- In March 2024, AstraZeneca's Ultomiris (ravulizumab-cwvz) has received approval from the US Food and Drug Administration (FDA) for the treatment of neuromyelitis optica spectrum disorder, a rare autoimmune condition affecting an estimated 6,000 adults in the United States. This approval marks a significant advancement in therapeutic options for patients living with this challenging disease. By providing a targeted treatment for NMOSD, AstraZeneca aims to improve patient outcomes and quality of life in this underserved population.
- In March 2024, AstraZeneca's Alexion announced that it has gained approval for the fourth indication of Ultomiris, allowing it to be utilized in the treatment of neuromyelitis optica spectrum disorder, a rare autoimmune condition. This milestone underscores the growing versatility of Ultomiris in addressing various severe autoimmune diseases. With this new indication, AstraZeneca aims to enhance treatment options for patients suffering from this challenging disorder, improving their chances for better health outcomes.
- In October 2023, Amgen revealed new findings from the phase 3 N-MOmentum clinical trial, which provide valuable insights into the presence of inflammatory biomarkers associated with neuromyelitis optica spectrum disorder (NMOSD). These findings further reinforce the "durable impact" of Uplizna (inebilizumab) in minimizing disease-related attacks. The study highlights the potential of Uplizna as an effective treatment option, emphasizing its role in managing the condition and improving patient outcomes by targeting the underlying inflammatory processes associated with NMOSD.
